Reported results
- Revenue recognized was $13.2 million for the third quarter of 2026 compared to $7.6 million in the prior year quarter.
- Research and development expenses were $53.8 million in the third quarter of 2026 compared to $45.9 million in the same period in 2025.
- General and administrative expenses were $25.4 million in the third quarter of 2026 compared to $18.1 million in the same period in 2025.
- Cash, cash equivalents, and marketable securities were $431.0 million as of September 30, 2026.
Guidance
- Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026.
- Wave remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy in the fourth quarter of 2026.
- Wave expects to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026.
- A clinical trial application (CTA) filing for WVE-008 is on track for the fourth quarter of 2026.
- Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028.
Price and volatility reaction
The stock moved +7.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -16.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 3.21 | 2026-10-26 |
| Close after release | 3.45 | 2026-10-27 |
| Realised move | +7.5% | close to close |
| 30d ATM IV change | -16.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.
